Heating creates a controlled stress that separates proteins by thermal behavior. Unbound proteins unfold and aggregate as temperature rises, reducing their representation in the soluble fraction, whereas ligand-bound proteins may remain soluble. The difference between treated and untreated samples across the temperature range therefore provides evidence that compound binding altered the stability of a cellular protein, rather than merely indicating compound presence.
An untreated sample provides the reference thermal behavior needed to interpret the treated sample. Researchers can examine how the soluble protein fraction changes across matching temperatures and determine whether treatment is associated with altered stability. This paired design helps distinguish a compound-related thermal effect from the unfolding and aggregation that occur during heating itself.
After heating, the assay focuses on the proteins that remain soluble rather than the aggregated material. Immunoblotting or mass spectrometry can quantify that soluble fraction, allowing researchers to track thermal stability changes for proteins of interest. The resulting measurements connect the physical heating response to evidence of compound engagement in the cellular sample.
Samples must include treated and untreated cells exposed to a temperature range, followed by measurement of the soluble fraction. Matching temperature conditions between samples is essential because interpretation depends on comparing their protein stability profiles. Researchers then use immunoblotting or mass spectrometry to quantify the retained soluble material and relate it to compound-associated changes.
Each compound can be evaluated by examining how treatment changes protein thermal stability relative to an untreated sample. Compounds that produce different stability patterns may show different degrees or profiles of target engagement. In drug discovery, these comparisons help prioritize activity while keeping the assessment tied to proteins in a native cellular environment.
Target engagement does not have to be assessed only for the intended protein. By measuring soluble-protein changes associated with treatment, researchers can look for interactions involving other cellular proteins as well. This makes the approach useful for identifying potential off-target interactions during drug discovery and for judging whether observed compound effects extend beyond the desired target.
Changes in protein stability measured after compound treatment can provide a cellular readout of drug action. These changes may help identify potential pharmacodynamic biomarkers, which are measurements related to how a compound affects its biological system. Such markers can connect molecular target engagement with compound treatment in cells, supporting medicine-focused drug discovery.